Loxiglumide, L-364, 718 and L-365, 260 Prevent the Inhibition of Spontaneous Acetylcholine Release from the Frontal Cerebral Cortex of Freely Moving Rat Peripherally Administered with Cholecystokinin-8S

The Japanese Journal of Pharmacology

Ikuko Kimura¹  Masayasu Kimura¹  Satomi Wakasono¹ 

[1] Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University

关键词: Cholecystokinin-8S;    Loxiglumide;    Spontaneous acetylcholine release (frontal cortex);   

DOI  :  10.1254/jjp.68.129

学科分类：药理学

来源: Nihon Yakuri Gakkai Henshuubu / Japanese Pharmacological Society

【 摘 要 】

References(14)Cited-By(1)We examined the effect of peripheral administration of cholecystokinin (CCK)-8S on spontaneous acetylcholine (ACh) release from the frontal cortex and its prevention by loxiglumide, L-364, 718 and L-365, 260 in freely moving rats using intracerebral microdialysis. Subcutaneously (s.c.) administered CCK-8S at 10 and 30 μg/kg significantly decreased the release of ACh. The inhibitory effect of 10 μg/kg (s.c.) CCK-8S was prevented by loxiglumide, a mixed type of CCK-A and -B-receptor antagonist, at 1 mg/kg (intraperitoneal) and 40 μg/rat (intracerebroventricular, i.c.v.); L-364, 718, a CCK-A-receptor antagonist, at 125 and 250 ng/rat (i.c.v.); and L-365, 260, a CCK-B-receptor antagonist at 250 ng/rat (i.c.v.). These results demonstrate that peripherally administered CCK-8S inhibits spontaneous ACh release from the frontal cortex through both central CCK-A (mainly) and -B receptors.

【 授权许可】

Unknown